Artificial intelligence and machine learning-aided drug discovery in central nervous system diseases: State-of-the-arts and future directions

Sezen Vatansever, Avner Schlessinger, Daniel Wacker, H. Ümit Kaniskan, Jian Jin, Ming Ming Zhou, Bin Zhang

Research output: Contribution to journalReview articlepeer-review

38 Scopus citations


Neurological disorders significantly outnumber diseases in other therapeutic areas. However, developing drugs for central nervous system (CNS) disorders remains the most challenging area in drug discovery, accompanied with the long timelines and high attrition rates. With the rapid growth of biomedical data enabled by advanced experimental technologies, artificial intelligence (AI) and machine learning (ML) have emerged as an indispensable tool to draw meaningful insights and improve decision making in drug discovery. Thanks to the advancements in AI and ML algorithms, now the AI/ML-driven solutions have an unprecedented potential to accelerate the process of CNS drug discovery with better success rate. In this review, we comprehensively summarize AI/ML-powered pharmaceutical discovery efforts and their implementations in the CNS area. After introducing the AI/ML models as well as the conceptualization and data preparation, we outline the applications of AI/ML technologies to several key procedures in drug discovery, including target identification, compound screening, hit/lead generation and optimization, drug response and synergy prediction, de novo drug design, and drug repurposing. We review the current state-of-the-art of AI/ML-guided CNS drug discovery, focusing on blood–brain barrier permeability prediction and implementation into therapeutic discovery for neurological diseases. Finally, we discuss the major challenges and limitations of current approaches and possible future directions that may provide resolutions to these difficulties.

Original languageEnglish
Pages (from-to)1427-1473
Number of pages47
JournalMedicinal Research Reviews
Issue number3
StatePublished - May 2021


  • Alzheimer's
  • CNS
  • Parkinson's
  • anesthesia
  • artificial intelligence
  • blood-brain barrier
  • depression
  • disease subtyping
  • drug design
  • drug discovery
  • machine learning
  • neurological diseases
  • pain treatment
  • schizophrenia
  • target identification


Dive into the research topics of 'Artificial intelligence and machine learning-aided drug discovery in central nervous system diseases: State-of-the-arts and future directions'. Together they form a unique fingerprint.

Cite this